Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?

Boone Capital established a new position in HealthEquity by buying 212,856 shares for $19.499738M, representing 6.12% of Boone’s $318.61M reportable U.S. equity AUM. HealthEquity traded at $74.36 on Feb. 17 (down 34.3% Y/Y, 52-week low $72.76) while reporting solid fundamentals: HSA count +7% YoY to 10.6M, Q3 sales $322.2M and Q3 net income $51.7M, with a forward P/E of 17 and market cap ~$6.43B.

Analysis

A concentrated, specialist manager adding a new position in a healthcare-fintech platform is a signal that the market’s current discount may be driven by transitory operational optics rather than a permanent impairment of the business model. The structural tailwinds—higher per-account fee capture, growing transaction volume through card/TPV rails, and optionality on custodial float monetization—create non-linear upside if enrollment and yield metrics inflect positively.

Second-order beneficiaries include payroll/benefits aggregation partners, card processors and custodial banks that pick up incremental payment flows and deposits; conversely, legacy third-party administrators and price-sensitive brokers are at risk of margin compression as platform incumbents consolidate client relationships. Regulatory or fiscal-policy changes that alter tax treatment of account types, and macro-driven compression of short-term yields on pooled balances, are the primary near- to medium-term value destroyers and will be the fastest to reprice the stock.

Event flow matters: near-term analyst focus will concentrate on enrollment cadence, TPV/fee yield per account and retention; medium-term re-rating requires durable operating leverage and higher float ROI. The consensus underweights the optionality from embedded financial services (card interchange, lending, sweep yields) and overweights headline top-line churn — a mismatch that creates asymmetric payoff for directional and relative-value trades into upcoming execution milestones.

Key Decisions for Investors

• Long HQY equity (6–12 month horizon): accumulate on weakness sized to 1–2% of portfolio, target asymmetric upside if enrollment and fee yield metrics beat consensus; mitigate tail risk with a protective 3–6 month put (10–15% OTM) sized at ~15% of long notional to limit drawdown to the low double digits.
• Defined-risk call spread (HQY, 9–12 month): buy longer-dated ITM/ATM calls and sell higher strikes to fund cost — expected return profile: capped upside ~50–80% vs cost outlay, breakeven on mid-single-digit improvement in key unit economics; use if you want leveraged exposure with limited capital at risk.
• Event-sequenced covered-write (HQY): buy shares and sell near-term OTM calls into each quarterly release to harvest premium and reduce net basis; roll or unwind within 7–14 days post-release depending on execution/outcomes — best for generating carry while waiting for re-rate.
• Pair trade (long HQY / short MDT, equal $ exposure, 6–12 months): hedge broader healthcare cyclical risk while remaining long fintech-specific re-rating; target relative return of +20–30% if platform fee growth outpaces device-cycle recovery, stop-loss if pair diverges by >15% intraperiod.